Genentech’s Lucentis Ships June 30 Following Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranibizumab, for the treatment of wet age-related macular degeneration, will be priced at a substantial premium to Pfizer/OSI's Macugen.